Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array

Cancer Science

Volumn 104, Issue 7, 2013, Pages 856-864

  Nishimura, Riki ^a   Takita, Junko ^a   Sato Otsubo, Aiko ^a   Kato, Motohiro ^b   Koh, Katsuyoshi ^b   Hanada, Ryoji ^b   Tanaka, Yukichi ^c   Kato, Keisuke ^d   Maeda, Daichi ^a   Fukayama, Masashi ^a   Sanada, Masashi ^a   Hayashi, Yasuhide ^e   Ogawa, Seishi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^c KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^d Ibaraki Children's Hospital   (Japan)

^e Gunma Children's Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELIC IMBALANCE; ARTICLE; CELL LINE; CHROMOSOME 12; CHROMOSOME 2; CHROMOSOME 8; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM;

CHILD; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GLYPICANS; GTP PHOSPHOHYDROLASES; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL;

EID: 84880728898     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12173     Document Type: Article

References (48)

1. Qualman SJ, Coffin CM, Newton WA et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1998; 1: 550-61.
2. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001; 20: 5736-46.
3. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997; 19: 483-91.
4. Visser M, Sijmons C, Bras J et al. Allelotype of pediatric rhabdomyosarcoma. Oncogene 1997; 15: 1309-14.
5. Pandita A, Zielenska M, Thorner P et al. Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. Neoplasia 1999; 1: 262-75.
6. Gordon AT, Brinkschmidt C, Anderson J et al. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosom Cancer 2000; 28: 220-6.
7. Bridge JA, Liu J, Weibolt V et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosom Cancer 2000; 27: 337-44.
8. Bridge JA, Liu J, Qualman SJ et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosom Cancer 2002; 33: 310-21.
9. Paulson V, Chandler G, Rakheja D et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosom Cancer 2011; 50: 397-408.
10. Nannya Y, Sanada M, Nakazaki K et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-9.
11. Yamamoto G, Nannya Y, Kato M et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-26.
12. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-4.
13. Okubo J, Takita J, Chen Y et al. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene 2012; 31: 4667-76.
14. Mei R, Galipeau PC, Prass C et al. Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res 2000; 10: 1126-37.
15. Iolascon A, Faienza MF, Coppola B et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosom Cancer 1996; 15: 217-22.
16. Wachtel M, Dettling M, Koscielniak E et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004; 64: 5539-45.
17. Sumegi J, Streblow R, Frayer RW et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosom Cancer 2010; 49: 224-36.
18. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-81.
19. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-9.
20. Galkin AV, Melnick JS, Kim S et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 2007; 104: 270-5.
21. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-9.
22. Bresler SC, Wood AC, Haglund EA et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011; 3: 108ra14.
23. Duijkers FA, Gaal J, Meijerink JP et al. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. Cell Oncol (Dordr). 2011; 34: 409-17.
24. Fang M, Toher J, Morgan M, Davison J, Tannenbaum S, Claffey K. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis. Cancer 2011; 117: 2024-34.
25. De Rienzo A, Balsara BR, Apostolou S, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene 2001; 20: 6245-9.
26. Sheffer M, Bacolod MD, Zuk O et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009; 106: 7131-6.
27. Besnard-Guérin C, Newsham I, Winqvist R, Cavenee WK. A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Hum Genet 1996; 97: 163-70.
28. Duan F, Smith LM, Gustafson DM et al. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosom Cancer 2012; 51: 662-74.
29. Missiaglia E, Williamson D, Chisholm J et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012; 30: 1670-7.
30. Barr FG, Duan F, Smith LM et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosom Cancer 2009; 48: 661-72.
31. Ehrbrecht A, Müller U, Wolter M et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 2006; 208: 554-63.
32. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003; 13: 507-18.
33. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol 2010; 28: 1240-6.
34. Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 2004; 24: 9726-35.
35. Kim B, Feldman EL. Insulin receptor substrate (IRS)-2, not IRS-1, protects human neuroblastoma cells against apoptosis. Apoptosis 2009; 14: 665-73.
36. Stöhr O, Hahn J, Moll L et al. Insulin receptor substrate-1 and -2 mediate resistance to glucose-induced caspase-3 activation in human neuroblastoma cells. Biochim Biophys Acta 2011; 1812: 573-80.
37. Shukla NN, Ameur N, Yilmaz I et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 2012; 18: 748-57.
38. Wagner PL, Stiedl AC, Wilbertz T et al. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 2011; 74: 118-23.
39. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012; 61: 673-84.
40. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
41. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003; 9: 5271-81.
42. Li F, Shi W, Capurro M, Filmus J. Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol 2011; 192: 691-704.
43. Williamson D, Selfe J, Gordon T et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res 2007; 67: 57-65.
44. Reichek JL, Duan F, Smith LM et al. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res 2011; 17: 1463-73.
45. Corao DA, Biegel JA, Coffin CM et al. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol 2009; 12: 275-83.
46. van Gaal JC, Flucke UE, Roeffen MH et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol 2012; 30: 308-15.
47. Pillay K, Govender D, Chetty R. ALK protein expression in rhabdomyosarcomas, Histopathology 2002; 41: 461-7.
48. Chen Y, Takita J, Mizuguchi M et al. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosom Cancer 2007; 46: 348-58.